Figure 4.

Analysis of immune cell subsets by flow cytometry. (A) Percentage of noncytotoxic T cells and NK/T cells at baseline. (B) Percentage of nonclassical monocytes over the course of therapy with nivolumab (at baseline, after 14 and after 28 days). (C) Percentage of monocytic myeloid-derived suppressor cells (MO-MDSC) over the course of therapy with nivolumab (at baseline, after 14 and after 28 days). Analysis was performed in the first four patients. Numbering of patients in the three panels is the same as reported in Table 2.